Compare FET & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FET | OLMA |
|---|---|---|
| Founded | 2005 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 850.2M | 949.3M |
| IPO Year | 2007 | 2020 |
| Metric | FET | OLMA |
|---|---|---|
| Price | $82.22 | $10.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $44.89 |
| AVG Volume (30 Days) | 181.9K | ★ 953.9K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.64 | 15.00 |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $791,474,000.00 | N/A |
| Revenue This Year | $7.35 | N/A |
| Revenue Next Year | $6.95 | N/A |
| P/E Ratio | $210.90 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.07 | $5.99 |
| 52 Week High | $87.42 | $36.26 |
| Indicator | FET | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 66.65 | 48.00 |
| Support Level | $54.55 | $10.71 |
| Resistance Level | $87.42 | $11.36 |
| Average True Range (ATR) | 3.54 | 0.45 |
| MACD | -0.69 | 0.01 |
| Stochastic Oscillator | 61.56 | 57.62 |
Forum Energy Technologies Inc is a manufacturing company serving the oil, natural gas, industrial, and renewable energy industries. Its products include engineered capital equipment, as well as products that are consumed in the drilling, well construction, production, and transportation of oil and natural gas. The company operates in two reportable segments: Drilling and Completions, and Artificial Lift and Downhole. Maximum revenue is generated from the Drilling and Completions segment, which offers products used in the drilling process, and other products like hydraulic fracturing pumps, ROVs and trenchers, submarine rescue vehicles, etc. Geographically, the firm generates maximum revenue from the U.S., followed by Canada, Middle East, Europe and Africa, Asia-Pacific, and Latin America.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.